Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | GALR2 | O43603 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151648 | 0.88 | TSHR (0.60) | TDP1GPR35TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL8051898 | 0.86 | GPR35 (0.56) | TDP1GPR35TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL7786752 | 0.86 | TDP1 (0.48) | TDP1GPR35TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL29483006 | 0.86 | TDP1 (0.48) | TDP1GPR35TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL102957 | 0.86 | MAPT (0.49) | TDP1GPR35TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL28035882 | 0.86 | TDP1 (0.48) | TDP1GPR35TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL4725194 | 0.86 | TDP1 (0.48) | TDP1GPR35TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL4725240 | 0.86 | TDP1 (0.48) | TDP1GPR35TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL26908112 | 0.83 | ERN1 (0.57) | TDP1GPR35TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL6930910 | 0.83 | ALDH1A1 (0.62) | TDP1SMN1; SMN2ALDH1A1L3MBTL1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023092175-A1 | NOVEL P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023092175-A1 | NOVEL P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2023-06-01 | — | — | WO | disclosed |
| WO-2012068211-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| US-20120129811-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2012068211-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| US-8039500-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-18 | — | — | US | disclosed |
| US-7714009-B2 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-25 | — | — | US | disclosed |
| EP-2125753-A1 | FUSED HETEROCYCLIC COMPOUNDS HAVING CRF ANTAGONISTIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008082003-A1 | FUSED HETEROCYCLIC COMPOUNDS HAVING CRF ANTAGONISTIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | WO | disclosed |
| EP-1677791-A4 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-12-07 | — | — | US | disclosed |
| EP-1677791-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005044793-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | CRHR1, CRHR2, CRH | TDP1 4718/4885GPR35 259/4885TSHR 291/4885 |
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | ENPP1, ENPP3, SMPD1 | TDP1 696/4885GPR35 4472/4885TSHR 3929/4885 |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | NPY4R, NR4A3, NR3C2 | TDP1 4581/4885GPR35 268/4885TSHR 278/4885 |
| US-20120129811-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP3, MMP13 | TDP1 365/4885GPR35 3668/4885TSHR 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.